Skip to content
  • EnglishEnglish
  • SvenskaSvenska
 

ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

  • About us
    • Management
    • Board of Directors
  • Diseases
    • Liver metastases
    • Gastric Cancer
  • Pipeline
    • Mangoral
    • Clinical Development Mangoral
    • Oncoral
    • Clinical Development Oncoral
    • Oncoral Phase 2 Plans
  • IR & Media
    • Press releases & News
    • Reports & Presentations
    • Share
    • Shareholders
    • Equity research
    • Subscribe to press releases
    • Ascelia Pharma in Media
    • IPO (completed 2019)
    • IR Contact
    • Financial calendar
    • CMD 2020
    • Events
  • Corporate governance
    • General Meeting
    • Articles of Association
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Commercialization Committee
    • Remuneration
    • Auditors
    • Internal control
  • Career
    • Open positions
    • Open applications
    • Our values
    • Meet us
  • Contact

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
AllRegulatoryAnnual reportInterim ReportNewsletterPress releaseYear end report

Year: 2017

2017-11-13 | Oncology-focused Ascelia Pharma strengthens its board of directors to support international expansion
Download
Presentation
Webcast
Excel
2017-09-14 | Ascelia Pharma strengthens its oncology product portfolio
Download
Presentation
Webcast
Excel

  • Ascelia Pharma AB

  • Hyllie Boulevard 34

  • 215 32 MALMÖ

  • Sweden

  • +46 735 179 118

Ascelia Pharma © 2019 | All Rights Reserved

Privacy policy Ascelia Pharma AB

We use cookies. Read more about cookies or read our Privacy Policy

Close
Video